A Phase 1 study designed to evaluate imaging characteristics of flortaucipir in the preclinical, prodromal and dementia phases of Alzheimer's disease.
Full record on ClinicalTrials.gov (NCT ID NCT04468347).
18F-AV-1451 PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's Disease
Avid Radiopharmaceuticals · Interventional, Non-randomized
154 views
★
★
★
★
★
Worth knowing
No randomised comparison group
Not a rating. A trial without these notes isn't free of limitations.
Overview
Results summary
Not reported
Outcome data
| Endpoint | Type | Result | Significance |
|---|---|---|---|
| Flortaucipir PET Imaging (Quantitative) | Primary | Not reported | Not reported |
| Number of Participants With Advanced AD Pattern Flortaucipir PET Scan and Relationship to Cognitive Status | Primary | Not reported | Not reported |
| Number of Participants With AD Pattern Flortaucipir PET Scan and Relationship to Cognitive Status | Primary | Not reported | Not reported |
Full results record on ClinicalTrials.gov.
Study design
- Phase
- Phase 1
- Study type
- Interventional
- Allocation
- Non-randomizedi
- Masking
- Open label
- Intervention model
- Parallel assignment
- Primary purpose
- Diagnostic
- Enrollment (final)
- 89 participants
- Started
- October 2014
- Actually completed
- February 2018
Recruitment criteria
Age range: ≥ 60 · Sex: All · Healthy volunteers: Accepts
Locations
0 sites participated during the trial period. Representative sites shown below; full historical record on ClinicalTrials.gov.
Sources
ClinicalTrials.gov — NCT04468347
Trial registry · primary record